Rezolute
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
275 Shoreline Dr Ste 500, Redwood City, ...Phone Number
(650) 206-4507Website
www.rezolutebio.comRevenue
-Stock Symbol
RZLTIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
2
1
1
About Rezolute
Rezolute strives to disrupt current treatment paradigms by developing transformative therapies for devastating rare and chronic metabolic diseases. Its novel therapies hold the potential to both significantly improve outcomes and reduce the treatment burden for patients, the treating physician, and the healthcare system. Patient, clinician, and advocate voices are integrated in the Company's drug development process, enabling Rezolute to boldly address a range of severe conditions. Rezolute is steadfast in its mission to create profound, positive, and lasting impact on patients' lives. The Company's lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism, a rare pediatric endocrine disorder. Rezolute is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema.Explore more
Rezolute Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rezolute your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Rezolute has new funding data
Check out if Rezolute is spiking on competitors!
Click to see if Rezolute had a recent Job posting/layoffs
Earning: See what the market has to say on Rezolute recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Rezolute
Rezolute, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Rezolute launches new products
Check if Rezolute has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Rezolute
Compare insights from companies similar to Rezolute, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Rezolute is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Rezolute is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Rezolute.
Rezolute financials insights
Gather financial insights about Rezolute, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Debt
$1.4M
2019
Share Placement
$45M
2020
Private Equity
$41M
2021
Debt
$30M
Rezolute Tech Stack
A closer look at the technologies used by Rezolute
See more technologies
Most Recent Scoops
Hiring Plans
Rezolute has more open roles in Operations than it has had at any time in the past 6 months. Areas of expertise include: Smartsheet, Project Coordination, Microsoft Teams, Project Management, and Supplier Development.
Hiring Plans
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Spending/Investment, Stake & Stock Ownership, Finance
Rezolute News & Media
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2026.Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared to placebo, across multiple pre-specified and post-hoc endpoints
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rezolute
Sign Up For FreeTo access detailed company insights
Rezolute strives to disrupt current treatment paradigms by developing transformative therapies for devastating rare and chronic metabolic diseases. Its novel therapies hold the potential to both significantly improve outcomes and reduce the treatment burden for patients, the treating physician, and the healthcare system. Patient, clinician, and adv... Read More
